Open an Account
search icon
1
NOTIFICATIONS
Best Algo trading app in India
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company has, on the recommendation of Nomination and Remuneration Committee, appointed Mr. Narotam Kumar Juneja (DIN: 01204817) as an additional director (in the capacity of Non-Executive Non-Independent Director) on the Board of Directors of the Company with effect from April 01, 2022. In accordance with the circular dated June 20, 2018, issued by the Stock Exchanges, we have got the confirmation from Mr. Narotam Kumar Juneja that he is not debarred from accessing the capital market and / or restrained from holding the office of Director by virtue of any order of SEBI or any other such authority. The details as required to be disclosed under the aforesaid Regulation 30 read with Clause 7 of Para A of Annexure I of SEBI Circular dated 09 September, 2015 is enclosed as Annexure - A to this letter.
01-04-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vistra ITCL (India) Ltd
22-03-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 17, 2022 for Soshil Kumar Jain, Dr Rajesh Jain & Sandeep Jain
17-03-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 17, 2022 for Soshil Kumar Jain, Dr Rajesh Jain, Sandeep Jain & Mrs Nirmala Jain
17-03-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Resignation of Director

 Pursuant to Regulation 30(2) read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that Mr. Shantanu Yeshwant Nalavadi, Non-Executive Nominee Director of the Company has, due to his professional commitments, tendered resignation from the Board of Directors of the Company vide his letter dated March 10, 2022. Mr. Shantanu Yeshwant Nalavadi was earlier nominated by Vistra ITCL (India) Limited acting as Debenture Trustee with respect to non-convertible debentures issued to India Resurgence Fund-Scheme 1, India Resurgence Fund-Scheme 2 and Piramal Enterprises Limited which have been fully redeemed on March 03,2022. The said resignation has become effective from March 10, 2022. You are requested to take the above information on record.
10-03-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 This is with reference to CDSL's Operating Instructions for Issuers/RTAs, which states that the Issuer/RTA shall inform the details of the securities dematerialized to all the Stock Exchanges where the securities are listed. Accordingly, we would like to inform you that no share has been dematerialized during the month of February, 2022. A copy of the certificate obtained from the Company's RTA viz. Skyline Financial Services Pvt. Ltd., regarding shares dematerialized as on February 28, 2022 is also enclosed herewith
07-03-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Intimation Of Redemption Of 79,800 Unrated, Unlisted, Redeemable, Non-Convertible Debentures (Ncds) Issued By Material Subsidiary Viz. Panacea Biotec Pharma Limited

 This is with reference to unrated, unlisted, redeemable, non-convertible debentures under Series 1A, Series 1B and Series 3 NCDs (NCDs) issued by Company's material wholly owned subsidiary company viz. Panacea Biotec Pharma Limited ('PBPL') to India Resurgence Fund - Scheme 1, India Resurgence Fund - Scheme 2 and Piramal Enterprises Limited ('Debenture Holders') and outstanding as on March 03, 2022. We also draw your attention to our earlier letter dated March 01, 2022 intimating about sale of domestic pharmaceutical formulation brands in India and Nepal by PBPL. In regard to the above we are pleased to inform that PBPL has fully redeemed the entire outstanding NCDs aggregating Rs.754.44 Crores together with redemption premium of Rs.343.63 Crores, out of the funds received by it in consideration of the above referred transaction. As a result of this, PBPL has now become a debt free company. This is for your kind information and record please.
04-03-2022

Mankind Pharma acquires Panacea's domestic formulation brands for Rs 1,872 cr

 As part of the arrangement, Mankind Pharma Ltd, has agreed to retain Panacea Biotec's sales and marketing team engaged in this business.
01-03-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements

 We hereby inform that as approved by the Board of Directors as well as shareholders of the Company and PBPL, the asset purchase agreement has been executed on February 28, 2022, for sale of pharmaceutical formulation brands of PBPL in India and Nepal and transfer of well-trained sales & marketing team engaged in domestic pharmaceutical business of PBPL to Mankind Pharma, for an aggregate consideration of INR 1,872 Crore plus GST. PBPL has also executed other definitive agreements including Intellectual Property Assignment Agreement, Patent License Agreement, Manufacturing & Supply Agreement and Transition Services Agreement. In this regard, as per Circular Number CIR/CFD/CMD/4/2015 dated September 09, 2015, please find the requisite details in the attached Annexure - 1. This is for your information and record please. Kindly acknowledge the receipt.
01-03-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 The Company and its material subsidiary viz. Panacea Biotec Pharma Ltd. ("PBPL") have entered into definitive agreements today i.e. 28.02.2022 for sale of Pharmaceutical Formulations Brands of PBPL for India and Nepal, to Mankind Pharma Limited at a total consideration of INR 1,872 Crore. As part of this arrangement, Mankind has agreed to retain Panacea Biotec's well-trained sales and marketing team engaged in this business. The above sale is in line with the Company's strategic plan to become debt free and focus on exports of Pharmaceutical formulations in US and other international markets besides the vaccine business in global markets. The divestment will ensure adequate liquidity for these businesses, drive investments in products under development and expanding capacities for key vaccine projects to drive future growth in a sustainable manner. A copy of Press Release being issued by Mankind Pharma Limited in this regard is enclosed for your kind reference and record please.
28-02-2022
Next Page
Close

Let's Open Free Demat Account